Report : Asia Pacific Patient Simulators Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Adult Patient Simulator, Infant Simulator, and Childbirth Simulator) and End User (Academic Institutes, Hospitals, and Military Organizations)
At 15.7% CAGR, the Asia Pacific Patient Simulators Market is speculated to be worth US$ 744.14 million by 2028, says Business Market Insights
According to Business Market Insights’ research, the Asia Pacific patient simulators market was valued at US$ 310.55 million in 2022 and is expected to reach US$ 744.14 million by 2028, registering a CAGR of 15.7% from 2022 to 2028. Growing technological advancements in patient simulators and increase in demand for minimally invasive treatment methods are the critical factors attributed to the Asia Pacific patient simulators market expansion.
There have been rapid advancements in healthcare technologies over the last few decades with the emergence of technologies such as virtual reality, augmented reality, artificial intelligence, robotics, 3D printing, and nanotechnology, and these will continue to shape the future of healthcare in the years to come. Advanced technology has made it possible that computer software can be integrated into manikins. The organs of one of these lifelike medical simulators, including their heart, blood vessels, lungs, and gastrointestinal tract, can also be made to respond to various human interventions during clinical simulation engagements. The computer software allows human patient simulators to replicate normal and abnormal bodily responses for educational and training purposes. Often these responses are initiated by several physical events, such as an asthma attack. Therapeutic interventions can also be replicated under certain circumstances, including representing a side effect of a medication. More advanced simulators allow learners to use mixed reality viewer lenses to visualize the internal anatomy of a simulated patient. With these lenses, students can learn skills through observation and remote active participation. For instance, Gaumard's most advanced product combines mixed reality technology with a high-fidelity birthing simulator. With mixed reality goggles, a learner can visualize the baby and cardinal movements during decent while engaging in the hands-on exercise of delivering the baby. In the event of a complication, the learner can observe the mother's and baby's anatomy. Suppose the baby is not descending through the birth canal. In that case, learners can now manipulate the simulator in a specific way and receive visual feedback indicating that their legs have been moved to the proper position. With patient simulators, learners can practice these skills repeatedly to gain the muscle memory and critical thinking skills needed to react quickly during complicated procedures. Thus, the growing technological advancement in simulation is expected to introduce new trends to the Asia Pacific patient simulators market.
On the contrary, high cost of patient simulators hurdles the growth of Asia Pacific patient simulators market.
Based on product, the Asia Pacific patient simulators market is segmented into adult patient simulator, infant simulator, and childbirth simulator. The adult patient simulator segment held 48.1% share of Asia Pacific patient simulators market in 2022, amassing US$ 149.44 million. It is projected to garner US$ 366.58 million by 2028 to expand at 16.1% CAGR during 2022–2028.
Based on end user, the Asia Pacific patient simulators market is segmented into academic institutes, hospitals, and military organizations. The academic institutes segment held 52.1% share of Asia Pacific patient simulators market in 2022, amassing US$ 161.75 million. It is projected to garner US$ 396.82 million by 2028 to expand at 16.1% CAGR during 2022–2028.
Based on country, the Asia Pacific patient simulators market has been categorized into China, India, Japan, South Korea, Australia, and the Rest of Asia Pacific. Our regional analysis states that China captured 30.2% share of Asia Pacific patient simulators market in 2022. It was assessed at US$ 93.74 million in 2022 and is likely to hit US$ 230.79 million by 2028, exhibiting a CAGR of 16.2% during the forecast period.
Key players dominating the Asia Pacific patient simulators market are CAE Inc, Gaumard Scientific Co Inc, Kyoto Kagaku Co Ltd, Laerdal Medical AS, Limbs & Things Ltd, Mentice AB, Simulab Corp, Surgical Science Sweden AB, and VirtaMed AG among others.
- In Oct 2020, Mentice AB signed a definitive agreement to acquire Vascular Simulations (VSI). The acquisition expanded Mentice's global leadership role within endovascular simulation by offering value solutions that support all stages of a medical device's development cycle.
- In April 2022, CAE Healthcare started deliveries of its newest high-fidelity paediatric patient simulator, CAE Aria. The Company ramped up production to accommodate demand for the medical manikin amid increasing challenges accessing paediatric patients for clinical training.
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: firstname.lastname@example.org